Chimeric Therapeutics Limited (CHM.AX)
| Previous close | 0.0310 |
| Open | 0.0310 |
| Bid | 0.0290 x 24502200 |
| Ask | 0.0300 x 16334300 |
| Day's range | 0.0290 - 0.0310 |
| 52-week range | 0.0230 - 0.0730 |
| Volume | |
| Avg. volume | 2,488,267 |
| Market cap | 24.702M |
| Beta (5Y monthly) | 1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings date | 29 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
GlobeNewswireChimeric Therapeutics To Attend BIO International Convention
SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the “Company”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is please to announce that Jennifer Chow, Chief Executive Officer and Managing Director, will present at the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston,
- GlobeNewswire
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial
New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, TexasEnrolment now open to patients with recurrent and/or progressive glioblastoma multiforme (GBM), the most common and most deadly primary brain cancer SYDNEY, Australia, June 04, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only clinical stage cell therapy company on the ASX, is pleased to announce activation of a Phase 1B clinical
